Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples